Four things to know · April 15, 2026
Noticed in days · Full benefit in weeks
Week 1-2
Improved digestive comfort, reduced GI irritation.
Week 2-4
Enhanced gastric protection and healing.
Week 4-8
Systemic healing benefits and overall wellness improvement.
Oral BPC-157 targets the gut directly. It's stable in stomach acid, which is unusual for a peptide. This makes it the preferred route for digestive issues, IBS/IBD support, and gastric protection. Higher doses are needed compared to injection (500mcg-2mg vs 250-500mcg) because oral absorption is less direct, but the gut-specific effects are stronger.
Oral protocols
| Protocol | Dose | Frequency |
|---|---|---|
| Gastric protection | 500mcg-1mg | 1-2x daily |
| General healing | 1-2mg | 1-2x daily |
| Ulcer prevention | 500mcg | 2x daily |
| Maintenance | 500mcg | 1x daily |
Protocols are from published research literature. This is not medical advice. Dosing should be determined by a licensed clinician.
What people report
Improved digestive comfort, reduced GI irritation.
Enhanced gastric protection and healing.
Systemic healing benefits and overall wellness improvement.
What to know
- ⚠Take on an empty stomach, 30 minutes before eating, for best absorption
- ⚠Mild digestive adjustment in the first few days is normal
- ⚠Avoid during pregnancy or breastfeeding
- ⚠If you take blood thinners, talk to your clinician first
- ⚠Prohibited by WADA (World Anti-Doping Agency). Not cleared for competitive sports
How BPC-157 works
When injected near an injury, BPC-157 concentrates locally rather than dispersing through the body. It works by triggering the growth of new blood vessels around damaged tissue, ramping up collagen production, and activating growth factors that accelerate the repair process. The reported effect is typically faster healing with improved tissue quality at the site.
Key benefits
- ✓Supports gastrointestinal repair and gut lining protection
- ✓Promotes new blood vessel growth around injured tissue
- ✓Accelerates healing across tendons, ligaments, muscles, and bones
- ✓Strengthens connective tissue through increased collagen production
- ✓Reduces local inflammation at the injury site
Regulatory status
Category 2. The FDA's pharmacy compounding advisory committee is scheduled to review BPC-157 on July 23, 2026, for potential addition to the 503A bulks list. The use under review: gut inflammation and inflammatory bowel conditions (ulcerative colitis). No formal rule change yet. Not FDA approved. Prohibited by WADA (added 2022) under S0, with no medical exemption available for athletes.
KEY RESEARCH · 5 PAPERS CITED
The Pep Dispatch
Follow the evidence on BPC-157 as it evolves.
Subscribe to find out what.
Next dispatch · May 2026 · Honest frequency: a few times a month
For the people who want to feel better — not just look up symptoms.